Ewa Klamerus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ewa Klamerus has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Sagnik Bhattacharyya
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
8 shared publications - Robin MacGregor Murray
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
6 shared publications Enrico Foglia
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, UK
5 shared publications- Natalia Petros
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
5 shared publications - Tabea Schoeler
Department of Computational Biology, University of Lausanne, Lausanne, Switzerland
5 shared publications E. Foglia
Department of Psychosis Studies, King's College London, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), Box PO 63, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
3 shared publications
Latest Publications
- 19 August 2019
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 50 (11) , 1862-1871
Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids
Background: Evidence has been accumulating regarding alterations in components of the endocannabinoid system in patients with psychosis. Of all the putative risk factors associated with psychosis, being at clinical high-risk for psychosis (CHR) has the strongest association with the onset of psychosis, and exposure to childhood trauma has been linked to an increased risk of development of psychotic disorder. We aimed to investigate whether being at-risk for psychosis and exposure to childhood trauma were associated with altered endocannabinoid levels.Method: We compared 33 CHR participants with 58 healthy controls (HC) and collected information about previous exposure to childhood trauma as well as plasma samples to analyse endocannabinoid levels.Results: Individuals with both CHR and experience of childhood trauma had higher N-palmitoylethanolamine (p < 0.001) and anandamide (p < 0.001) levels in peripheral blood compared to HC and those with no childhood trauma. There was also a significant correlation between N-palmitoylethanolamine levels and symptoms as well as childhood trauma.Conclusions: Our results suggest an association between CHR and/or childhood maltreatment and elevated endocannabinoid levels in peripheral blood, with a greater alteration in those with both CHR status and history of childhood maltreatment compared to those with either of those risks alone. Furthermore, endocannabinoid levels increased linearly with the number of risk factors and elevated endocannabinoid levels correlated with the severity of CHR symptoms and extent of childhood maltreatment. Further studies in larger cohorts, employing longitudinal designs are needed to confirm these findings and delineate the precise role of endocannabinoid alterations in the pathophysiology of psychosis.
- 19 August 2019
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 50 (11) , 1862-1871
Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids
Background: Evidence has been accumulating regarding alterations in components of the endocannabinoid system in patients with psychosis. Of all the putative risk factors associated with psychosis, being at clinical high-risk for psychosis (CHR) has the strongest association with the onset of psychosis, and exposure to childhood trauma has been linked to an increased risk of development of psychotic disorder. We aimed to investigate whether being at-risk for psychosis and exposure to childhood trauma were associated with altered endocannabinoid levels.Method: We compared 33 CHR participants with 58 healthy controls (HC) and collected information about previous exposure to childhood trauma as well as plasma samples to analyse endocannabinoid levels.Results: Individuals with both CHR and experience of childhood trauma had higher N-palmitoylethanolamine (p < 0.001) and anandamide (p < 0.001) levels in peripheral blood compared to HC and those with no childhood trauma. There was also a significant correlation between N-palmitoylethanolamine levels and symptoms as well as childhood trauma.Conclusions: Our results suggest an association between CHR and/or childhood maltreatment and elevated endocannabinoid levels in peripheral blood, with a greater alteration in those with both CHR status and history of childhood maltreatment compared to those with either of those risks alone. Furthermore, endocannabinoid levels increased linearly with the number of risk factors and elevated endocannabinoid levels correlated with the severity of CHR symptoms and extent of childhood maltreatment. Further studies in larger cohorts, employing longitudinal designs are needed to confirm these findings and delineate the precise role of endocannabinoid alterations in the pathophysiology of psychosis.
- Open Access
- 1 September 2017
- Published by Elsevier in Psychiatry Research
- Vol. 255, 36-41
Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis
- 1 September 2017
- Published by Elsevier in Psychiatry Research
- Vol. 255, 36-41
Open AccessEffect of continued cannabis use on medication adherence in the first two years following onset of psychosis
- Open Access
- 1 August 2017
- Published by Elsevier in The Lancet Psychiatry
- Vol. 4 (8) , 627-633
Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis
- 1 August 2017
- Published by Elsevier in The Lancet Psychiatry
- Vol. 4 (8) , 627-633
Open AccessPoor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis
- 9 February 2017
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 47 (10) , 1691-1705
Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis
Background: Substance use may increase the risk of non-adherence to antipsychotics, resulting in negative outcomes in patients with psychosis.Method: We aimed to quantitatively summarize evidence regarding the effect of cannabis use, the most commonly used illicit drug amongst those with psychosis, on adherence to antipsychotic medication. Studies were identified through a systematic database search. Adopting random-effects models, pooled odds ratios (OR) for risk of non-adherence to antipsychotic medications were calculated comparing: cannabis-users at baseline v. non-users at baseline; non users v. continued cannabis users at follow-up; non-users v. former users at follow-up; former users v. current users.Results: Fifteen observational studies (n = 3678) were included. Increased risk of non-adherence was observed for cannabis users compared to non-users (OR 2.46, n = 3055). At follow-up, increased risk of non-adherence was observed for current users compared to non-users (OR 5.79, n = 175) and former users (OR 5.5, n = 192), while there was no difference between former users and non-users (OR 1.12, n = 187).Conclusions: Cannabis use increases the risk of non-adherence and quitting cannabis use may help adherence to antipsychotics. Thus, cannabis use may represent a potential target for intervention to improve medication adherence in those with psychosis.
- 9 February 2017
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 47 (10) , 1691-1705
Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis
Background: Substance use may increase the risk of non-adherence to antipsychotics, resulting in negative outcomes in patients with psychosis.Method: We aimed to quantitatively summarize evidence regarding the effect of cannabis use, the most commonly used illicit drug amongst those with psychosis, on adherence to antipsychotic medication. Studies were identified through a systematic database search. Adopting random-effects models, pooled odds ratios (OR) for risk of non-adherence to antipsychotic medications were calculated comparing: cannabis-users at baseline v. non-users at baseline; non users v. continued cannabis users at follow-up; non-users v. former users at follow-up; former users v. current users.Results: Fifteen observational studies (n = 3678) were included. Increased risk of non-adherence was observed for cannabis users compared to non-users (OR 2.46, n = 3055). At follow-up, increased risk of non-adherence was observed for current users compared to non-users (OR 5.79, n = 175) and former users (OR 5.5, n = 192), while there was no difference between former users and non-users (OR 1.12, n = 187).Conclusions: Cannabis use increases the risk of non-adherence and quitting cannabis use may help adherence to antipsychotics. Thus, cannabis use may represent a potential target for intervention to improve medication adherence in those with psychosis.
- Open Access
- 1 November 2016
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 73 (11) , 1173-1179
Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis
Understanding the nature of the association between cannabis use and psychotic disorders is crucial for the formulation of evidence-based health policies concerning cannabis, especially in light of changing public attitudes and legalization of cannabis use in several states in the United States and other countries.1- 4 This understanding is particularly important because psychotic disorders, such as schizophrenia, cause the most severe health loss of all human disorders5,6 and are associated with considerable financial burden.7,8 Psychotic disorders are also associated with a high rate of comorbid abuse of cannabis,9,10 the most commonly used illicit drug worldwide.11
- 1 November 2016
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 73 (11) , 1173-1179
Open AccessAssociation Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis
Understanding the nature of the association between cannabis use and psychotic disorders is crucial for the formulation of evidence-based health policies concerning cannabis, especially in light of changing public attitudes and legalization of cannabis use in several states in the United States and other countries.1- 4 This understanding is particularly important because psychotic disorders, such as schizophrenia, cause the most severe health loss of all human disorders5,6 and are associated with considerable financial burden.7,8 Psychotic disorders are also associated with a high rate of comorbid abuse of cannabis,9,10 the most commonly used illicit drug worldwide.11
- Open Access
- 1 October 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (10) , 947-953
Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study
- 1 October 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (10) , 947-953
Open AccessEffects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study
- 1 August 2016
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 209 (2) , 169-170
Impact of childhood trauma on risk of relapse requiring psychiatric hospital admission for psychosis
Summary: Relapse in psychosis typically necessitates admission to hospital placing a significant financial burden on the health service. Exposure to childhood trauma is associated with an increased risk of psychosis, however, the extent to which this influences relapse is unclear. This report summarises current research investigating the influence of childhood trauma on relapse requiring psychiatric hospital admission for psychosis. Seven studies were included; two revealed a positive association between childhood trauma and relapse admission, two studies found a negative relationship and three found no significant difference. Inconsistent current evidence suggests a need for further research in this area.
- 1 August 2016
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 209 (2) , 169-170
Impact of childhood trauma on risk of relapse requiring psychiatric hospital admission for psychosis
Summary: Relapse in psychosis typically necessitates admission to hospital placing a significant financial burden on the health service. Exposure to childhood trauma is associated with an increased risk of psychosis, however, the extent to which this influences relapse is unclear. This report summarises current research investigating the influence of childhood trauma on relapse requiring psychiatric hospital admission for psychosis. Seven studies were included; two revealed a positive association between childhood trauma and relapse admission, two studies found a negative relationship and three found no significant difference. Inconsistent current evidence suggests a need for further research in this area.
- Top Cited Papers
- 1 March 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (3) , 215-225
Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis
- 1 March 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (3) , 215-225
Top Cited PapersContinued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis